ArticleAngewandte Chemie (International ed. in English)2026
Novel Non-Cytotoxic Acylphosphinates and Acylphosphine Oxides Photoinitiators.
Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
This study focused on the design and synthesis of a series of novel acylphosphine oxide (APO) and acylphosphinate photoinitiators based either on diphenylphosphine oxide (DPO) or 9,10-dihydro-9-oxa-10-phosphaphenanthrene 10-oxide (DOPO), systematically investigating the structure-property relationships in terms of photochemical performance, polymerization efficiency and cytotoxicity. Polymerization experiments demonstrated that DPO-based photoinitiators exhibit excellent photopolymerization efficiency, while the structurally optimized DOPO-based Type I photoinitiators also exhibit good reactivity. Biocompatibility experiments indicate that acylphosphinates (e.g., the (6-oxidodibenzo[c,e][1,2]oxaphosphinin-6-yl)(2,4,6-trimethoxyphenyl)methanone (TMO-DOPO) derivative) exhibit no significant toxicity toward C3H10 T1/2 mouse mesenchymal stem cells, significantly outperforming the traditional 2,4,6-trimethylbenzoyldiphenylphosphine oxide (TPO) photoinitiator. These results highlight the DOPO role as a functional core in Type I initiation systems, providing an effective strategy for developing novel, efficient, and low-toxicity photoinitiators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.